(NUVB) Nuvation Bio - Ratings and Ratios
Taletrectinib, Safusidenib, NUV-1511, NUV-868
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 78.2% |
| Value at Risk 5%th | 110% |
| Relative Tail Risk | -14.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.64 |
| Alpha | 197.41 |
| CAGR/Max DD | 1.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.383 |
| Beta | 1.353 |
| Beta Downside | 1.009 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.13% |
| Mean DD | 30.08% |
| Median DD | 31.45% |
Description: NUVB Nuvation Bio November 30, 2025
Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharma focused on oncology, headquartered in New York and founded in 2018. Its lead candidate, taletrectinib, is an oral ROS1 inhibitor targeting ROS1-positive non-small cell lung cancer (NSCLC), currently in Phase 2 trials. The pipeline also includes Safusidenib (mutant IDH1 inhibitor, Phase 2), NUV-1511 (a drug-drug conjugate for multiple advanced solid tumors), and NUV-868 (a BRD4-targeting BET inhibitor).
Key metrics as of Q3 2024: the company reported cash and equivalents of roughly $55 million, giving it an estimated 12-month runway at current burn (~$4-5 million per month). Taletrectinib’s Phase 2 data showed an objective response rate (ORR) of 45 % in ROS1-positive NSCLC patients, comparable to the benchmark drug entrectinib, and the trial is enrolling an additional 80 patients to strengthen statistical power. The global ROS1-positive NSCLC market is estimated at $200 million annually, growing at ~8 % CAGR, driven by increasing molecular testing and targeted-therapy adoption.
Biotech sector fundamentals remain supportive: R&D tax credits and a robust pipeline financing environment have helped similar-size companies secure $100-$150 million in equity raises in the past 12 months, suggesting NUVB could tap comparable capital if needed. For a deeper dive into valuation assumptions and scenario analysis, you may find ValueRay’s analyst tools useful.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-217.5m TTM) > 0 and > 6% of Revenue (6% = 1.60m TTM) |
| FCFTA -0.32 (>2.0%) and ΔFCFTA -14.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1904 % (prev 18.8k%; Δ -16.9kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.32 (>3.0%) and CFO -190.0m > Net Income -217.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 8.48 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (342.4m) change vs 12m ago 25.16% (target <= -2.0% for YES) |
| Gross Margin 54.26% (prev -10.59%; Δ 64.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.56% (prev 0.47%; Δ 4.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -203.2 (EBITDA TTM -215.0m / Interest Expense TTM 1.06m) >= 6 (WARN >= 3) |
Altman Z'' -1.53
| (A) 0.85 = (Total Current Assets 577.5m - Total Current Liabilities 68.1m) / Total Assets 601.6m |
| (B) -1.79 = Retained Earnings (Balance) -1.08b / Total Assets 601.6m |
| warn (B) unusual magnitude: -1.79 — check mapping/units |
| (C) -0.37 = EBIT TTM -216.4m / Avg Total Assets 586.6m |
| (D) 1.18 = Book Value of Equity 325.9m / Total Liabilities 275.7m |
| Total Rating: -1.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 39.06
| 1. Piotroski 1.0pt |
| 2. FCF Yield -6.86% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.18 |
| 5. Debt/Ebitda 0.19 |
| 6. ROIC - WACC (= -61.77)% |
| 7. RoE -54.99% |
| 8. Rev. Trend 86.60% |
| 9. EPS Trend 0.76% |
What is the price of NUVB shares?
Over the past week, the price has changed by -4.28%, over one month by +13.45%, over three months by +177.64% and over the past year by +241.22%.
Is NUVB a buy, sell or hold?
- Strong Buy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NUVB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.3 | 25.8% |
| Analysts Target Price | 11.3 | 25.8% |
| ValueRay Target Price | 8.8 | -1.8% |
NUVB Fundamental Data Overview December 27, 2025
P/S = 122.0194
P/B = 10.0152
Beta = 1.587
Revenue TTM = 26.7m USD
EBIT TTM = -216.4m USD
EBITDA TTM = -215.0m USD
Long Term Debt = 47.1m USD (from longTermDebt, last quarter)
Short Term Debt = 7.49m USD (from shortTermDebt, last quarter)
Debt = 57.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -41.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.77b USD (3.26b + Debt 57.5m - CCE 549.0m)
Interest Coverage Ratio = -203.2 (Ebit TTM -216.4m / Interest Expense TTM 1.06m)
FCF Yield = -6.86% (FCF TTM -190.2m / Enterprise Value 2.77b)
FCF Margin = -711.3% (FCF TTM -190.2m / Revenue TTM 26.7m)
Net Margin = -813.1% (Net Income TTM -217.5m / Revenue TTM 26.7m)
Gross Margin = 54.26% ((Revenue TTM 26.7m - Cost of Revenue TTM 12.2m) / Revenue TTM)
Gross Margin QoQ = 74.47% (prev 46.70%)
Tobins Q-Ratio = 4.61 (Enterprise Value 2.77b / Total Assets 601.6m)
Interest Expense / Debt = 0.87% (Interest Expense 501.0k / Debt 57.5m)
Taxrate = -0.0% (0.0 / -55.8m)
NOPAT = -216.4m (EBIT -216.4m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 8.48 (Total Current Assets 577.5m / Total Current Liabilities 68.1m)
Debt / Equity = 0.18 (Debt 57.5m / totalStockholderEquity, last quarter 325.9m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -41.3m / EBITDA -215.0m)
Debt / FCF = 0.22 (negative FCF - burning cash) (Net Debt -41.3m / FCF TTM -190.2m)
Total Stockholder Equity = 395.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.15% (Net Income -217.5m / Total Assets 601.6m)
RoE = -54.99% (Net Income TTM -217.5m / Total Stockholder Equity 395.5m)
RoCE = -48.90% (EBIT -216.4m / Capital Employed (Equity 395.5m + L.T.Debt 47.1m))
RoIC = -50.94% (negative operating profit) (NOPAT -216.4m / Invested Capital 424.8m)
WACC = 10.82% (E(3.26b)/V(3.32b) * Re(11.0%) + D(57.5m)/V(3.32b) * Rd(0.87%) * (1-Tc(-0.0)))
Discount Rate = 11.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 25.06%
Fair Price DCF = unknown (Cash Flow -190.2m)
EPS Correlation: 0.76 | EPS CAGR: 23.95% | SUE: 2.59 | # QB: 1
Revenue Correlation: 86.60 | Revenue CAGR: 119.9% | SUE: 2.88 | # QB: 7
EPS next Quarter (2026-03-31): EPS=-0.19 | Chg30d=-0.067 | Revisions Net=+1 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.28 | Chg30d=+0.240 | Revisions Net=-1 | Growth EPS=+37.8% | Growth Revenue=+218.6%
Additional Sources for NUVB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle